Close Menu

Precision Oncology Business, Policy & Funding

Breaking news on Precision Oncology business, policy & funding.

The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.

The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.

The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.

The approval from China's National Medical Products Administration expands access to the drug in a country with a significant lung cancer burden.

The company's pipeline includes a KIT inhibitor that will move into clinical studies this year and an EGFR inhibitor in preclinical studies.